Pfizer gamed the FDA on its change from PBS to Tris plus a patent sheds light on the seriousness of particle size and "stable folded RNA" with the Pfizer's purple-topped vials
On June 12, 2022, after four Pfizer injections, my very healthy mom was suddenly diagnosed with stage-IV pancreatic cancer in her left inguinal groin lymph node, B-cell lymphoma, and melanoma. Her immune system had failed completely. The fast-growing tumors spread to her bones, breaking them from the inside. She lived, suffering, until December 13.
I was her full-time caregiver.
In 2023, day by day, using memories, photos, text conversations, medical records, my journal, and my mom’s journal, I chronicled the story of her disease on Facebook. I told about the progression of her illness, the failed medical response, her unimaginable pain, her experience, my experience,and how her spirit refused to be broken.
I am currently in the process of editing and rewriting, on Substack.
My mom represents millions of people who were deceived, intimidated or forced into receiving an injection. Her story is all of our story.
I love BioNTech addiction to Bacterial Endotoxin, Lipid A and Lipopeptides as "Adjuvants", as shown in the Patent US20230414747A1 from April 2021 you mention written by characters we should follow:
Saccharolipids describe compounds in which fatty acids are linked directly to a sugar backbone, forming structures that are compatible with membrane bilayers. In the saccharolipids, a monosaccharide substitutes for the glycerol backbone present in glycerolipids and glycerophospholipids. The most familiar saccharolipids are the acylated glucosamine precursors of the Lipid A component of the lipopolysaccharides in Gram-negative bacteria. Typical lipid A molecules are disaccharides of glucosamine, which are derivatized with as many as seven fatty-acyl chains. The minimal lipopolysaccharide required for growth in E. coli is Kdo2-Lipid A, a hexa-acylated disaccharide of glucosamine that is glycosylated with two 3-deoxy-D-manno-octulosonic acid (Kdo) residues.
Section [0959]
The pharmaceutical compositions of the present disclosure may comprise one or more adjuvants or may be administered with one or more adjuvants. The term “adjuvant” relates to a compound which prolongs, enhances or accelerates an immune response. Adjuvants comprise a heterogeneous group of compounds such as oil emulsions (e.g., Freund's adjuvants), mineral compounds (such as alum), bacterial products (such as Bordetella pertussis toxin), or immune-stimulating complexes. Examples of adjuvants include, without limitation, LPS, GP96, CpG oligodeoxynucleotides, growth factors, and cyctokines, such as monokines, lymphokines, interleukins, chemokines. The chemokines may be IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12, INFa, INF-γ, GM-CSF, LT-a. Further known adjuvants are aluminium hydroxide, Freund's adjuvant or oil such as Montanide® ISA51. Other suitable adjuvants for use in the present disclosure include lipopeptides, such as Pam3Cys, as well as lipophilic components, such as saponins, trehalose-6,6-dibehenate (TDB), monophosphoryl lipid-A (MPL), monomycoloyl glycerol (MMG), or glucopyranosyl lipid adjuvant (GLA).
1. Did we know what we were doing? Yes, obviously.
2. Again, did we know what we were doing? Absolutely no, we did not study long-term impact, we didn’t bother about limitation or switching off mechanisms, we did not bother about actual in vivo distribution and toxicity, and we did not care about following an expensive full-cycle experimental stage (10 years or so).
3. Was it possible that the richest pharma corporation in the world was not interested in performing the proper due diligence BEFORE even trying to consider human application? (rhetorical)
4. Did we care about developing a product intended for human use in full respect of all applicable laws? Next question. please.
5. Do we care now about any of the above? This is not a real question.
6. Has this product given the world any benefit? Absolutely. The mRNA concept is slowly replacing old medicine wherever we can embed it.
We are at the opening threshold for the new world. One day the world will be free of any diseases. In our wildest fantasies, we can imagine that some of us will survive to this day.
They are murderers.
On June 12, 2022, after four Pfizer injections, my very healthy mom was suddenly diagnosed with stage-IV pancreatic cancer in her left inguinal groin lymph node, B-cell lymphoma, and melanoma. Her immune system had failed completely. The fast-growing tumors spread to her bones, breaking them from the inside. She lived, suffering, until December 13.
I was her full-time caregiver.
In 2023, day by day, using memories, photos, text conversations, medical records, my journal, and my mom’s journal, I chronicled the story of her disease on Facebook. I told about the progression of her illness, the failed medical response, her unimaginable pain, her experience, my experience,and how her spirit refused to be broken.
I am currently in the process of editing and rewriting, on Substack.
My mom represents millions of people who were deceived, intimidated or forced into receiving an injection. Her story is all of our story.
https://mamaearthdesignshop.substack.com?utm_source=navbar&utm_medium=web&r=368d5r
More on Tris Bait and Switch
https://geoffpain.substack.com/p/tromethamine-is-a-hazardous-substance
I love BioNTech addiction to Bacterial Endotoxin, Lipid A and Lipopeptides as "Adjuvants", as shown in the Patent US20230414747A1 from April 2021 you mention written by characters we should follow:
Steffen Panzner
Ugur Sahin
Jorrit-Jan Krijger
Kaushik Thanki
Bakul Subodh Bhatnagar
Ramin Darvari
Sumit Luthra
Serguei A. Tchessalov
https://geoffpain.substack.com/p/tlr2-diseases-caused-by-bacterial
Section [0855]
Saccharolipids describe compounds in which fatty acids are linked directly to a sugar backbone, forming structures that are compatible with membrane bilayers. In the saccharolipids, a monosaccharide substitutes for the glycerol backbone present in glycerolipids and glycerophospholipids. The most familiar saccharolipids are the acylated glucosamine precursors of the Lipid A component of the lipopolysaccharides in Gram-negative bacteria. Typical lipid A molecules are disaccharides of glucosamine, which are derivatized with as many as seven fatty-acyl chains. The minimal lipopolysaccharide required for growth in E. coli is Kdo2-Lipid A, a hexa-acylated disaccharide of glucosamine that is glycosylated with two 3-deoxy-D-manno-octulosonic acid (Kdo) residues.
Section [0959]
The pharmaceutical compositions of the present disclosure may comprise one or more adjuvants or may be administered with one or more adjuvants. The term “adjuvant” relates to a compound which prolongs, enhances or accelerates an immune response. Adjuvants comprise a heterogeneous group of compounds such as oil emulsions (e.g., Freund's adjuvants), mineral compounds (such as alum), bacterial products (such as Bordetella pertussis toxin), or immune-stimulating complexes. Examples of adjuvants include, without limitation, LPS, GP96, CpG oligodeoxynucleotides, growth factors, and cyctokines, such as monokines, lymphokines, interleukins, chemokines. The chemokines may be IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12, INFa, INF-γ, GM-CSF, LT-a. Further known adjuvants are aluminium hydroxide, Freund's adjuvant or oil such as Montanide® ISA51. Other suitable adjuvants for use in the present disclosure include lipopeptides, such as Pam3Cys, as well as lipophilic components, such as saponins, trehalose-6,6-dibehenate (TDB), monophosphoryl lipid-A (MPL), monomycoloyl glycerol (MMG), or glucopyranosyl lipid adjuvant (GLA).
Segalla wrote about this problem last year: https://www.ijvtpr.com/index.php/IJVTPR/article/view/68
They knew PBS was a BAD idea, they did it anyways.
There is a video by Segalla on this topic https://vimeo.com/807279310
In plain English:
1. Did we know what we were doing? Yes, obviously.
2. Again, did we know what we were doing? Absolutely no, we did not study long-term impact, we didn’t bother about limitation or switching off mechanisms, we did not bother about actual in vivo distribution and toxicity, and we did not care about following an expensive full-cycle experimental stage (10 years or so).
3. Was it possible that the richest pharma corporation in the world was not interested in performing the proper due diligence BEFORE even trying to consider human application? (rhetorical)
4. Did we care about developing a product intended for human use in full respect of all applicable laws? Next question. please.
5. Do we care now about any of the above? This is not a real question.
6. Has this product given the world any benefit? Absolutely. The mRNA concept is slowly replacing old medicine wherever we can embed it.
We are at the opening threshold for the new world. One day the world will be free of any diseases. In our wildest fantasies, we can imagine that some of us will survive to this day.
I would love to hear your comments on this one I wrote, many other great people have already added their take so the comments alone are worth reading!
This was no lab leak. It was a deliberate release in multiple locations. WHO is responsible, I have no idea!
More here; https://truthaddict.substack.com/p/lab-leak-zoonotic-spillover-or-deliberate